Functional significance of erythropoietin in renal cell carcinoma

Morais, Christudas, Johnson, David W., Vesey, David A. and Gobe, Glenda C. (2013) Functional significance of erythropoietin in renal cell carcinoma. BMC Cancer, 13 14.1-14.7. doi:10.1186/1471-2407-13-14

Author Morais, Christudas
Johnson, David W.
Vesey, David A.
Gobe, Glenda C.
Title Functional significance of erythropoietin in renal cell carcinoma
Journal name BMC Cancer   Check publisher's open access policy
ISSN 1471-2407
Publication date 2013-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1186/1471-2407-13-14
Open Access Status DOI
Volume 13
Start page 14.1
End page 14.7
Total pages 7
Place of publication London, United Kingdom
Publisher BioMed Central
Collection year 2014
Language eng
Abstract One of the molecules regulated by the transcription factor, hypoxia inducible factor (HIF), is the hypoxia-responsive hematopoietic factor, erythropoietin (EPO). This may have relevance to the development of renal cell carcinoma (RCC), where mutations of the von Hippel-Lindau (VHL) gene are major risk factors for the development of familial and sporadic RCC. VHL mutations up-regulate and stabilize HIF, which in turn activates many downstream molecules, including EPO, that are known to promote angiogenesis, drug resistance, proliferation and progression of solid tumours. HIFs typically respond to hypoxic cellular environment. While the hypoxic microenvironment plays a critical role in the development and progression of tumours in general, it is of special significance in the case of RCC because of the link between VHL, HIF and EPO. EPO and its receptor, EPOR, are expressed in many cancers, including RCC. This limits the use of recombinant human EPO (rhEPO) to treat anaemia in cancer patients, because the rhEPO may be stimulatory to the cancer. EPO may also stimulate epithelial-mesenchymal transition (EMT) in RCC, and pathological EMT has a key role in cancer progression. In this mini review, we summarize the current knowledge of the role of EPO in RCC. The available data, either for or against the use of EPO in RCC patients, are equivocal and insufficient to draw a definitive conclusion.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article number 14

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 24 Feb 2013, 00:34:14 EST by System User on behalf of Medicine - Princess Alexandra Hospital